Conclusion Combination therapy with SGLT-2i and GLP-1RA may provide superior cardiovascular, weight, and Hemoglobin A1c outcomes versus monotherapy despite higher gastrointestinal adverse events
However, there are important, clinically significant drug interactions to consider
10.1186/s40170-020-0209-8 168 RomanoA.MartelF
Already authorised, Lillys tirzepatide targets both GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP) receptor, which has a complementary role in stimulating insulin secretion and reducing appetite
We are exposed every day to toxins like cigarette smoke, automobile exhaust, food preservatives, and dental amalgam and our body depends on GSH for their removal
Individuals with certain digestive conditions that can affect B12 absorption